🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10954237

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954228

1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use there

NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953209

Treating tumors using TTFields combined with a PARP inhibitor

The Board of Regents of the University of Texas System · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10952997

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10952996

ALK5 inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947238

Wee1 kinase inhibitors and methods of making and using the same

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941183

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941140

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10940141

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934349

Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934332

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

The Regents of the University of California · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934305

SHMT inhibitors

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934302

SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934274

Quinoline derivatives as TAM RTK inhibitors

Lead Discovery Center GmbH · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934299

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Valo Early Discovery, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933022

Protease inhibitor-containing compositions, compositions comprising same, and methods for

Oramed Ltd. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10932484

Inhibitory activity of acetogenins against Listeria monocytogenes

INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10927118

Inhibitors of influenza virus replication and uses thereof

SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10927130

Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-spe

Valo Early Discovery, Inc. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10919877

Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeut

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10913740

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10913711

Potent and selective inhibitors of monoamine transporters; method of making; and use there

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10913709

STAT3 inhibitor formulation

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10912779

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/m

Asana BioSciences, LLC · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted